Pacific Biosciences (PACB) Stock Forecast & Price Target

Compare

2,849 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PACB Analyst Ratings

Moderate Buy

3 Buy

2 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Pacific

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PACB Stock 12 Month Forecast

Average Price Target

$2.40

▲(27.66% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Pacific Biosciences in the last 3 months. The average price target is $2.40 with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 27.66% change from the last price of $1.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,2.289230769230769,2.3484615384615384,2.4076923076923076,2.4669230769230768,2.526153846153846,2.5853846153846156,2.644615384615385,2.703846153846154,2.763076923076923,2.8223076923076924,2.8815384615384616,2.940769230769231,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,2.243076923076923,2.256153846153846,2.269230769230769,2.2823076923076924,2.295384615384615,2.3084615384615383,2.3215384615384616,2.3346153846153848,2.3476923076923075,2.3607692307692307,2.373846153846154,2.3869230769230767,{"y":2.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.23,2.212307692307692,2.1946153846153846,2.1769230769230767,2.1592307692307693,2.1415384615384614,2.123846153846154,2.106153846153846,2.0884615384615386,2.0707692307692307,2.0530769230769232,2.0353846153846153,2.0176923076923075,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.00

Average Price Target$2.40

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

$1.5→$2

Hold

6.38%

Upside

Reiterated

12/15/25

Pacific Biosciences (PACB) Gets a Hold from Barclays

David Westenberg

Piper Sandler

$1.5→$2

Hold

6.38%

Upside

Reiterated

11/11/25

PacBio price target raised to $2 from $1.50 at Piper SandlerPacBio price target raised to $2 from $1.50 at Piper Sandler

Mason Carrico

Stephens

$1.8→$2

Buy

6.38%

Upside

Reiterated

11/10/25

PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens

Daniel Brennan

TD Cowen

Buy

59.57%

Upside

Reiterated

11/06/25

Pacific Biosciences: Strong Consumable Growth and New Product Launches Drive Buy Rating

Kyle Mikson CFA

Canaccord Genuity

$1.35→$3

Buy

59.57%

Upside

Reiterated

11/05/25

Pacific Biosciences: Overcoming Short-Term Challenges with Strategic Innovations and Long-Term Growth ProspectsWe reiterate our BUY rating on Pacific Biosciences (PACB) shares and maintain our price target at $3. We remain constructive after a mixed 3Q25, as we are hopeful sentiment may gradually improve going forward. After the market close on PacBio posted 3Q25 revenue that was below our estimate and FactSet consensus. The performance was impacted by lower Revio pricing and delayed Vega shipments. On a positive note, Revio pull-through increased q/q and total gross margin improved nicely. The company narrowed its 2025 revenue guidance (lowering the midpoint). Indeed, macro challenges may pressure PacBio's growth profile in the relative near term. We think the company is positioned to return to solid growth in 2026 given its progress with clinical customers and population-scale programs. PacBio's new multi-use SMRT cells could also unlock larger projects for customers.

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

Hold

6.38%

Upside

Reiterated

08/10/25

Morgan Stanley Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

Eve Burstein

Bernstein

$1.5→$1.7

Buy

-9.57%

Downside

Reiterated

08/08/25

Pacific Biosciences (PACB) Gets a Buy from Bernstein

Tycho Peterson

Jefferies

$3.5→$3

Buy

59.57%

Upside

Reiterated

05/09/25

Pacific Biosciences of California (PACB) PT Lowered to $3 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Pacific Biosciences of California (NASDAQ: PACB) to $3.00 (from $3.50) while maintaining a Buy rating.

Sung Ji Nam

Scotiabank

Buy

6.38%

Upside

Reiterated

04/10/25

Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)

Ross Osborn

Cantor Fitzgerald

$2.5

Buy

32.98%

Upside

Reiterated

03/18/25

Cantor Fitzgerald reiterates Overweight Rating on Pacific Biosciences of California (PACB)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.50 price target on Pacific Biosciences of California (NASDAQ: PACB).

Matthew Sykes

Goldman Sachs

$1.75→$1.5

Hold

-20.21%

Downside

Reiterated

02/18/25

Pacific Biosciences of California (PACB) PT Lowered to $1.50 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Pacific Biosciences of California (NASDAQ: PACB) to $1.50 (from $1.75) while maintaining a Neutral rating.

John Sourbeer

UBS

$2→$1.5

Hold

-20.21%

Downside

Reiterated

02/14/25

Pacific Biosciences of California (PACB) PT Lowered to $1.50 at UBSUBS analyst John Sourbeer lowered the price target on Pacific Biosciences of California (NASDAQ: PACB) to $1.50 (from $2.00) while maintaining a Neutral rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

$1.5→$2

Hold

6.38%

Upside

Reiterated

12/15/25

Pacific Biosciences (PACB) Gets a Hold from Barclays

David Westenberg

Piper Sandler

$1.5→$2

Hold

6.38%

Upside

Reiterated

11/11/25

PacBio price target raised to $2 from $1.50 at Piper SandlerPacBio price target raised to $2 from $1.50 at Piper Sandler

Mason Carrico

Stephens

$1.8→$2

Buy

6.38%

Upside

Reiterated

11/10/25

PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens

Daniel Brennan

TD Cowen

Buy

59.57%

Upside

Reiterated

11/06/25

Pacific Biosciences: Strong Consumable Growth and New Product Launches Drive Buy Rating

Kyle Mikson CFA

Canaccord Genuity

$1.35→$3

Buy

59.57%

Upside

Reiterated

11/05/25

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

Hold

6.38%

Upside

Reiterated

08/10/25

Morgan Stanley Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

Eve Burstein

Bernstein

$1.5→$1.7

Buy

-9.57%

Downside

Reiterated

08/08/25

Pacific Biosciences (PACB) Gets a Buy from Bernstein

Tycho Peterson

Jefferies

$3.5→$3

Buy

59.57%

Upside

Reiterated

05/09/25

Sung Ji Nam

Scotiabank

Buy

6.38%

Upside

Reiterated

04/10/25

Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)

Ross Osborn

Cantor Fitzgerald

$2.5

Buy

32.98%

Upside

Reiterated

03/18/25

Matthew Sykes

Goldman Sachs

$1.75→$1.5

Hold

-20.21%

Downside

Reiterated

02/18/25

John Sourbeer

UBS

$2→$1.5

Hold

-20.21%

Downside

Reiterated

02/14/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacific Biosciences

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

+5.22%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +5.22% per trade.

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

+3.81%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +3.81% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

8/17 ratings generated profit

Average Return

-9.61%

reiterated a buy rating last month

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -9.61% per trade.

2 Years

xxx

Success Rate

10/17 ratings generated profit

Average Return

-6.21%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.82% of your transactions generating a profit, with an average return of -6.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PACB Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PACB has received 6 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. PACB average Analyst price target in the past 3 months is 2.40.

Each month's total comprises the sum of three months' worth of ratings.

PACB Financial Forecast

PACB Earnings Forecast

Next quarter’s earnings estimate for PACB is -$0.15 with a range of -$0.19 to -$0.13. The previous quarter’s EPS was -$0.13. PACB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.

PACB Sales Forecast

Next quarter’s sales forecast for PACB is $41.80M with a range of $40.40M to $42.81M. The previous quarter’s sales results were $38.44M. PACB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.

PACB Stock Forecast FAQ

What is PACB’s average 12-month price target, according to analysts?

Based on analyst ratings, Pacific Biosciences’s 12-month average price target is 2.40.

What is PACB’s upside potential, based on the analysts’ average price target?

Pacific Biosciences has 27.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PACB a Buy, Sell or Hold?

Pacific Biosciences has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.

What is Pacific Biosciences’s price target?

The average price target for Pacific Biosciences is 2.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $2.00. The average price target represents 27.66% Increase from the current price of $1.88.

What do analysts say about Pacific Biosciences?

Pacific Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of PACB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Pacific Biosciences (PACB) Stock Forecast & Price Target

PACB Analyst Ratings

PACB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pacific Biosciences

PACB Analyst Recommendation Trends

PACB Financial Forecast

PACB Earnings Forecast

PACB Sales Forecast

PACB Stock Forecast FAQ

Detailed List of Analyst Forecasts